AMENDMENTS TO THE CLAIMS

1. (Original) A compound represented by the formula:



wherein m is 1 or 2;

R^1 is a halogen atom or an optionally halogenated C_{1-2} alkyl group;

one of R^2 and R^3 is a hydrogen atom and the other is a group represented by the formula:



or



wherein n is 3 or 4; R^4 is a C_{1-4} alkyl group substituted by 1 or 2 hydroxy groups, or a salt thereof.

2. (Original) A compound as claimed in claim 1, wherein R^1 is fluoro or trifluoromethyl, or a salt thereof.

3. (Original) A compound as claimed in claim 1, wherein R^2 is a group represented by the formula:



and R^3 is a hydrogen atom; or

R^2 is a hydrogen atom and R^3 is a group represented by the formula:



or a salt thereof.

4. (Original) A compound as claimed in claim 1, wherein R^2 is a group represented by the formula:



and R^3 is a hydrogen atom, or a salt thereof.

5. (Original) A compound as claimed in claim 1, wherein m is 1;

R^1 is 4-trifluoromethyl;

R^2 is a group represented by the formula:



and R^3 is a hydrogen atom, or a salt thereof.

6. (Currently Amended) A compound as claimed in claim 1, which is

~~1-(4-{4-[(2-{(E)-2-[4-(trifluoromethyl)phenyl]ethenyl}-1,3-oxazol-4-yl)methoxy]phenyl}butyl)-1H-1,2,3-triazole;~~

1-(3-{3-[(2-{(E)-2-[4-(trifluoromethyl)phenyl]ethenyl}-1,3-oxazol-4-yl)methoxy]phenyl}propyl)-1H-1,2,3-triazole, or 3-(1-{4-[4-({2-[(E)-2-(2,4-difluorophenyl)ethenyl]-1,3-oxazol-4-yl}methoxy)phenyl]butyl}-1H-imidazol-2-yl)-1,2-propanediol, or a salt thereof.

7. (Original) A method for producing a compound as claimed in claim 1 or a salt thereof comprising reacting a compound represented by the formula:



wherein X is a leaving group; the other symbols have the same meanings as defined in claim 1, or a salt thereof, with a compound represented by the formula:



wherein the symbols have the same meanings as defined in claim 1, or a salt thereof.

8. (Original) A pro-drug of a compound as claimed in claim 1 or a salt thereof.

9. (Original) A pharmaceutical composition containing a compound as claimed in claim 1 or a salt thereof or a pro-drug thereof.

10. (Original) A pharmaceutical composition as claimed in claim 9, which is a tyrosine kinase inhibitor.

11. (Original) A pharmaceutical composition as claimed in claim 9, which is an agent for preventing or treating cancer.

12. (Original) A pharmaceutical composition as claimed in claim 11, wherein the cancer is breast cancer or prostate cancer.

13. (Original) A pharmaceutical composition as claimed in claim 11, wherein the cancer is lung cancer.

14. (Original) A pharmaceutical composition which combines a compound as claimed in claim 1 or a salt thereof or a pro-drug thereof and other anti-cancer agents.

15. (Original) A pharmaceutical composition which combines a compound as claimed in claim 1 or a salt thereof or a pro-drug thereof and hormonal therapeutic agents.

16. (Original) The pharmaceutical composition as claimed in claim 15, wherein the hormonal therapeutic agent is a LH-RH modulator.

17. (Original) The pharmaceutical composition as claimed in claim 16, wherein the LH-RH modulator is LH-RH antagonist.

18. (Original) The pharmaceutical composition as claimed in claim 17, wherein the LH-RH antagonist is leuprorelin or a salt thereof.

19. (Original) A method for inhibiting tyrosine-kinase which comprises administering an effective amount of a compound as claimed in claim 1 or a salt thereof or a pro-drug thereof to mammals.

20. (Original) A method for preventing or treating cancer which comprises administering an effective amount of a compound as claimed in claim 1 or a salt thereof or a pro-drug thereof to mammals.

21. (Original) A method for preventing or treating cancer which comprises combining (1) administering an effective amount of a compound as claimed in claim 1 or a salt thereof or a pro-drug thereof to mammals and (2) 1 to 3 selected from the group consisting (i) administering an effective amount of other anti-cancer agents to mammals, (ii) administering an effective amount of hormonal therapeutic agents to mammals and (iii) non-drug therapy.

22. (Original) The method as claimed in claim 21 wherein non-drug therapy is surgery, hypertensive chemotherapy, genetherapy, thermotherapy, cryotherapy, laser cauterization and/or radiotherapy.

23. (Original) A method for preventing or treating cancer which comprises administering in combination of an effective amount of a compound as claimed in claim 1 or a salt thereof or a pro-drug thereof and an effective amount of other anti-cancer agents to mammals.

24. (Original) A method for preventing or treating cancer which comprises administering in combination of an effective amount of a compound as claimed in claim 1 or a salt thereof or a pro-drug thereof and an effective amount of hormonal therapeutic agents to mammals.

25. (Original) The method as claimed in claim 24, wherein the hormonal therapeutic agent is a LH-RH modulator.

26. (Original) The method as claimed in claim 25, wherein the LH-RH modulator is LH-RH antagonist.

27. (Original) The method as claimed in claim 26, wherein the LH-RH antagonist is leuprorelin or a salt thereof.

28. (Original) A method for preventing or treating cancer which comprises administering an effective amount of a compound as claimed in claim 1 or a salt thereof or a pro-drug thereof to mammals before surgery, hypertensive chemotherapy, genetherapy, thermotherapy, cryotherapy, laser cauterization and/or radiotherapy.

29. (Original) A method for preventing or treating cancer which comprises administering an effective amount of a compound as claimed in claim 1 or a salt thereof or a pro-drug thereof to mammals after surgery, hypertensive chemotherapy, genetherapy, thermotherapy, cryotherapy, laser cauterization and/or radiotherapy.

30. (Original) A method for preventing or treating cancer which comprises administering in combination of an effective amount of a compound as claimed in claim 1 or a salt thereof or a pro-drug thereof and an effective amount of other anti-cancer agents to mammals before surgery, hypertensive chemotherapy, genetherapy, thermotherapy, cryotherapy, laser cauterization and/or radiotherapy.

31. (Original) A method for preventing or treating cancer which comprises administering in combination of an effective amount of a compound as claimed in claim 1 or a salt thereof or a pro-drug thereof and an effective amount of other anti-cancer agents to mammals before surgery, hypertensive chemotherapy, genetherapy, thermotherapy, cryotherapy, laser cauterization and/or radiotherapy.

32. (Original) The method as claimed in claim 31, wherein the hormonal therapeutic agent is a LH-RH modulator.

33. (Original) The method as claimed in claim 32, wherein the LH-RH modulator is LH-RH antagonist.

34. (Original) The method as claimed in claim 33, wherein the LH-RH antagonist is leuprorelin or a salt thereof.

35. (Original) A method for preventing or treating cancer which comprises administering in combination of an effective amount of a compound as claimed in claim 1 or a salt thereof or a pro-drug thereof and an effective amount of other anti-cancer agents to mammals after surgery, hypertensive chemotherapy, genetherapy, thermotherapy, cryotherapy, laser cauterization and/or radiotherapy.

36. (Original) A method for preventing or treating cancer which comprises administering in combination of an effective amount of a compound as claimed in claim 1 or a salt thereof or a pro-drug thereof and an effective amount of other anti-cancer agents to mammals after surgery, hypertensive chemotherapy, genetherapy, thermotherapy, cryotherapy, laser cauterization and/or radiotherapy.

37. (Original) The method as claimed in claim 36, wherein the hormonal therapeutic agent is a LH-RH modulator.

38. (Original) The method as claimed in claim 37, wherein the LH-RH modulator is LH-RH antagonist.

39. (Original) The method as claimed in claim 38, wherein the LH-RH antagonist is leuprorelin or a salt thereof.

40. (Cancelled)

41. (Cancelled)

42. (Original) A compound represented by the formula:



wherein R^{1a} is fluoro or trifluoromethyl, X^1 is a leaving group, and n is 3 or 4, or a salt thereof.

43. (Original) A compound as claimed in claim 42, wherein X^1 is a halogen atom.

44. (Cancelled)